早期乳腺癌预处理中性粒细胞/淋巴细胞比值缺乏预后价值。

IF 2 4区 医学 Q2 OBSTETRICS & GYNECOLOGY Breast Care Pub Date : 2022-12-01 Epub Date: 2022-06-03 DOI:10.1159/000525287
Maria Del Rosario Sifón, Nicolas Marcolini, Maria Julia Barber, Ignacio Mclean, Manglio Rizzo, Sergio Rivero, Maria Victoria Costanzo, Adrian Nervo, Gabriel Crimi, Florencia Perazzo, Estrella Mariel Levy, Pablo Mandó
{"title":"早期乳腺癌预处理中性粒细胞/淋巴细胞比值缺乏预后价值。","authors":"Maria Del Rosario Sifón, Nicolas Marcolini, Maria Julia Barber, Ignacio Mclean, Manglio Rizzo, Sergio Rivero, Maria Victoria Costanzo, Adrian Nervo, Gabriel Crimi, Florencia Perazzo, Estrella Mariel Levy, Pablo Mandó","doi":"10.1159/000525287","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is a highly heterogeneous disease with large differences in the risk of recurrence. An elevated neutrophil-to-lymphocyte ratio (NLR) is correlated with a poor prognosis in a variety of tumors, and although it is still controversial in breast cancer, there are multiple studies, including meta-analysis, suggesting this. The purpose of this study was to analyze the prognostic value of preoperative NLR in an Argentine population of patients with nonmetastatic breast cancer, not exposed to neoadjuvant treatment.</p><p><strong>Methods: </strong>Retrospective multicenter cohort study that includes patients over 18 years of age from three centers in the city and province of Buenos Aires who have had surgery for early breast cancer between January 1, 1999, and December 31, 2014. Based on the previous literature, a cutoff value of 2.0 was defined.</p><p><strong>Results: </strong>A total of 791 patients were eligible for the analysis. Median age was 55 years (IQR 45-65). Median NLR was 1.92 (IQR 1.50-2.56). The distribution of groups according to the 8th edition of the AJCC was 54.1% for stage I, 35.6% stage II, and 10.4% stage III. Among the different tumor phenotypes, 79.0% were HR+/HER2-, 11.4% were HR+ or-/HER2+, and 9.2% were HR-/HER2-. With a median follow-up of 5.3 years, 112 patients (14.2%) had disease recurrence. Stage III patients had a higher NLR than stage I and stage II patients (<i>p</i> = 0.002). The rest of the clinical and pathological characteristics did not show differences in the groups according to NLR. There were no differences in relapse-free survival according to the NLR (<i>p</i> = 0.37), and it did not change after adjusting for other prognostic variables.</p><p><strong>Conclusion: </strong>We consider it is important to determine the efficacy of prognostic markers that are easily accessible and of simple, systematic application. However, NLR does not appear to be an independent prognostic factor for recurrence in our population. In this sense, we consider it is important to publish negative results in order to avoid publication bias.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801394/pdf/","citationCount":"0","resultStr":"{\"title\":\"Lack of Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in Early Breast Cancer.\",\"authors\":\"Maria Del Rosario Sifón, Nicolas Marcolini, Maria Julia Barber, Ignacio Mclean, Manglio Rizzo, Sergio Rivero, Maria Victoria Costanzo, Adrian Nervo, Gabriel Crimi, Florencia Perazzo, Estrella Mariel Levy, Pablo Mandó\",\"doi\":\"10.1159/000525287\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Breast cancer is a highly heterogeneous disease with large differences in the risk of recurrence. An elevated neutrophil-to-lymphocyte ratio (NLR) is correlated with a poor prognosis in a variety of tumors, and although it is still controversial in breast cancer, there are multiple studies, including meta-analysis, suggesting this. The purpose of this study was to analyze the prognostic value of preoperative NLR in an Argentine population of patients with nonmetastatic breast cancer, not exposed to neoadjuvant treatment.</p><p><strong>Methods: </strong>Retrospective multicenter cohort study that includes patients over 18 years of age from three centers in the city and province of Buenos Aires who have had surgery for early breast cancer between January 1, 1999, and December 31, 2014. Based on the previous literature, a cutoff value of 2.0 was defined.</p><p><strong>Results: </strong>A total of 791 patients were eligible for the analysis. Median age was 55 years (IQR 45-65). Median NLR was 1.92 (IQR 1.50-2.56). The distribution of groups according to the 8th edition of the AJCC was 54.1% for stage I, 35.6% stage II, and 10.4% stage III. Among the different tumor phenotypes, 79.0% were HR+/HER2-, 11.4% were HR+ or-/HER2+, and 9.2% were HR-/HER2-. With a median follow-up of 5.3 years, 112 patients (14.2%) had disease recurrence. Stage III patients had a higher NLR than stage I and stage II patients (<i>p</i> = 0.002). The rest of the clinical and pathological characteristics did not show differences in the groups according to NLR. There were no differences in relapse-free survival according to the NLR (<i>p</i> = 0.37), and it did not change after adjusting for other prognostic variables.</p><p><strong>Conclusion: </strong>We consider it is important to determine the efficacy of prognostic markers that are easily accessible and of simple, systematic application. However, NLR does not appear to be an independent prognostic factor for recurrence in our population. In this sense, we consider it is important to publish negative results in order to avoid publication bias.</p>\",\"PeriodicalId\":9310,\"journal\":{\"name\":\"Breast Care\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801394/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breast Care\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000525287\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/6/3 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000525287","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/6/3 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:乳腺癌是一种高度异质性的疾病,其复发风险差异很大。中性粒细胞与淋巴细胞比值(NLR)升高与多种肿瘤预后不良相关,尽管在乳腺癌中仍存在争议,但包括meta分析在内的多项研究均表明了这一点。本研究的目的是分析术前NLR在阿根廷未接受新辅助治疗的非转移性乳腺癌患者中的预后价值。方法:回顾性多中心队列研究,纳入1999年1月1日至2014年12月31日期间在布宜诺斯艾利斯市和省的三个中心接受过早期乳腺癌手术的18岁以上患者。在前人文献的基础上,定义截断值2.0。结果:共有791例患者符合分析条件。中位年龄55岁(IQR 45-65)。中位NLR为1.92 (IQR为1.50-2.56)。根据第8版AJCC的分组分布,第一阶段为54.1%,第二阶段为35.6%,第三阶段为10.4%。在不同肿瘤表型中,HR+/HER2-占79.0%,HR+或-/HER2+占11.4%,HR-/HER2-占9.2%。中位随访5.3年,112例(14.2%)患者出现疾病复发。III期患者的NLR高于I期和II期患者(p = 0.002)。其余临床及病理特征按NLR组间无差异。根据NLR,无复发生存率无差异(p = 0.37),在调整其他预后变量后,无复发生存率无变化。结论:我们认为确定易于获取和简单、系统应用的预后标志物的疗效是重要的。然而,NLR似乎不是我们人群中复发的独立预后因素。从这个意义上说,我们认为发表负面结果以避免发表偏倚是很重要的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Lack of Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in Early Breast Cancer.

Background: Breast cancer is a highly heterogeneous disease with large differences in the risk of recurrence. An elevated neutrophil-to-lymphocyte ratio (NLR) is correlated with a poor prognosis in a variety of tumors, and although it is still controversial in breast cancer, there are multiple studies, including meta-analysis, suggesting this. The purpose of this study was to analyze the prognostic value of preoperative NLR in an Argentine population of patients with nonmetastatic breast cancer, not exposed to neoadjuvant treatment.

Methods: Retrospective multicenter cohort study that includes patients over 18 years of age from three centers in the city and province of Buenos Aires who have had surgery for early breast cancer between January 1, 1999, and December 31, 2014. Based on the previous literature, a cutoff value of 2.0 was defined.

Results: A total of 791 patients were eligible for the analysis. Median age was 55 years (IQR 45-65). Median NLR was 1.92 (IQR 1.50-2.56). The distribution of groups according to the 8th edition of the AJCC was 54.1% for stage I, 35.6% stage II, and 10.4% stage III. Among the different tumor phenotypes, 79.0% were HR+/HER2-, 11.4% were HR+ or-/HER2+, and 9.2% were HR-/HER2-. With a median follow-up of 5.3 years, 112 patients (14.2%) had disease recurrence. Stage III patients had a higher NLR than stage I and stage II patients (p = 0.002). The rest of the clinical and pathological characteristics did not show differences in the groups according to NLR. There were no differences in relapse-free survival according to the NLR (p = 0.37), and it did not change after adjusting for other prognostic variables.

Conclusion: We consider it is important to determine the efficacy of prognostic markers that are easily accessible and of simple, systematic application. However, NLR does not appear to be an independent prognostic factor for recurrence in our population. In this sense, we consider it is important to publish negative results in order to avoid publication bias.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Breast Care
Breast Care 医学-妇产科学
CiteScore
4.40
自引率
4.80%
发文量
45
审稿时长
6-12 weeks
期刊介绍: ''Breast Care'' is a peer-reviewed scientific journal that covers all aspects of breast biology. Due to its interdisciplinary perspective, it encompasses articles on basic research, prevention, diagnosis, and treatment of malignant diseases of the breast. In addition to presenting current developments in clinical research, the scope of clinical practice is broadened by including articles on relevant legal, financial and economic issues.
期刊最新文献
ASCO 2024: Personal Insights and a Look into the Future from an International Expert Group. Association of Aromatase Inhibitor-Induced Musculoskeletal Symptoms with Central Sensitization-Related Symptoms: A Cross-Sectional Study. Vitamin D and breast cancer risk: evaluating the association and effective risk reduction Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients with Positive Nodes Using Low-Cost Dual Dye Technique: Identifying Factors Associated with Adequate False Negative Rate Threshold. Translating Evidence into Practice: A Review of Clinical Practice and Outcomes following the Adoption of an Early Post-Mastectomy Discharge Protocol in a Nigerian Hospital.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1